Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

National Health Investors Q3 normalized FFO per share falls; net income up on gain from NHC portfolio sale

By Reuters News


Overview

  • US healthcare REIT's Q3 normalized FFO per share fell 15% year-over-year

  • Net income surged on large gain from NHC portfolio sale

  • Company completed significant acquisitions and dispositions during the quarter


Outlook

  • Company expects 2026 NAREIT FFO per diluted share of $4.68 to $4.70

  • Company projects 2026 FAD attributable to common stockholders of $236.6 mln to $237.7 mln

  • Company expects 2026 same store SHOP NOI growth of 1% to 3% on 15 properties


Result Drivers

  • SHOP SEGMENT ACQUISITIONS - Co said higher resident fees and services were mainly driven by acquisition of 20 properties in the SHOP segment since Q4 2025

  • PROPERTY DISPOSITIONS - Rental income fell due to sale of 42 properties and transition of seven properties to SHOP segment

  • HIGHER EXPENSES - General and administrative costs rose, mainly from increased compensation and professional fees


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Normalized FFO Per Share

$1.12


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the specialized reits peer group is "buy"

  • Wall Street's median 12-month price target for National Health Investors, Inc. is $80.00, about 12.3% above its November 9 closing price of $71.23

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 22 three months ago


Reuters Recommended Reads

  • Nov 9 - P3 Health Partners Q3 returns to profit

  • Nov 8 - RadNet beats Q3 adjusted EPS estimates, lifts 2026 outlook

  • Nov 9 - Surgery Partners Inc Q3 revenue misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.